logo

FULC

Fulcrum Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

FULC fundamentals

Fulcrum Therapeutics (FULC) released its earnings on Oct 29, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.31 (YoY +11.43%), missed estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.31
+11.43%
Report date
Oct 29, 2025
FULC Earnings Call Summary for Q3,2025
  • Pociredir shows promising SCD data: 12mg cohort achieved 15.7% HbF induction, 50% VOC reduction, and all Grade 1 AEs. 20mg cohort enrollment complete, with ASH 2025 data expected.
  • Open-label extension launched: Addresses patient demand for continued treatment post-PIONEER.
  • Strong financial position: $200.6M cash runway supports operations into 2028.
  • Market potential: 20,000 U.S. SCD patients meet inclusion criteria, with global addressable market of 7.7M.
  • Regulatory momentum: End-of-Phase I meeting with FDA planned for Q1 2026.
EPS
Revenue

Revenue & Expenses

Key Indicators

Fulcrum Therapeutics (FULC) key financial stats and ratios, covering profitability, financial health, and leverage.
Fulcrum Therapeutics (FULC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Fulcrum Therapeutics (FULC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Fulcrum Therapeutics (FULC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Fulcrum Therapeutics (FULC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Fulcrum Therapeutics (FULC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield